Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| P3 Health Partners Inc.PIII · Entity 4562 | Director | August 06, 2025 | January 23, 2026 |
| SANUWAVE Health, Inc.SNWW · Entity 7321 | Director | February 20, 2020 | February 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
P3 Health Partners Inc.
Report date August 06, 2025 · Filed January 23, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 6,331 |
Reported balance
After 2025-08-06 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-08-06 · Grant · Acquired 2,000 · Balance 6,331 F1: Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest upon the earlier of the Company's 2026 annual stockholder meeting and the one-year anniversary of the grant date. F2: This amended Form 4 is being filed to correct Column 5 of Table I, which inadvertently reported the number of securities beneficially owned by the Reporting Person prior to the Company's 1-for-50 reverse stock split, which became effective on April 11, 2025. This amended Form 4 is being filed solely to correct the number of securities beneficially owned by the Reporting Person following the reverse stock split. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest upon the earlier of the Company's 2026 annual stockholder meeting and the one-year anniversary of the grant date.
F2: This amended Form 4 is being filed to correct Column 5 of Table I, which inadvertently reported the number of securities beneficially owned by the Reporting Person prior to the Company's 1-for-50 reverse stock split, which became effective on April 11, 2025. This amended Form 4 is being filed solely to correct the number of securities beneficially owned by the Reporting Person following the reverse stock split.
SANUWAVE Health, Inc.
Report date February 20, 2020 · Filed February 21, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2030-02-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-02-20 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2025 Filed Aug 8, 2025 18:47 UTC | P3 Health Partners Inc. PIII · Entity 4562 | GrantClass A Common Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-039346 · wk-form4_1754693250.xml · nonDerivative · entry 1 Price Thomas Edmunds · CIK 0001804153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,561 F1 · shares: Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest in one year from date of grant. Read SEC document |
| August 06, 2025 Filed Jan 23, 2026 18:08 UTC Amendment | P3 Health Partners Inc. PIII · Entity 4562 | GrantClass A Common Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001804153-26-000001 · wk-form4a_1769209685.xml · nonDerivative · entry 1 Price Thomas Edmunds · CIK 0001804153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,331 F1 · shares: Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest upon the earlier of the Company's 2026 annual stockholder meeting and the one-year anniversary of the grant date. F2 · balance_after: This amended Form 4 is being filed to correct Column 5 of Table I, which inadvertently reported the number of securities beneficially owned by the Reporting Person prior to the Company's 1-for-50 reverse stock split, which became effective on April 11, 2025. This amended Form 4 is being filed solely to correct the number of securities beneficially owned by the Reporting Person following the reverse stock split. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 17:44 UTC | P3 Health Partners Inc. PIII · Entity 4562 | GrantStock Option (Right to Buy) · Derivative | 482,640 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001628280-24-027580 · wk-form4_1718055858.xml · derivative · entry 1 Price Thomas Edmunds · CIK 0001804153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,640 Underlying: Class A Common Stock · 482,640 shares Expires 2034-06-06 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 6, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| October 23, 2023 Filed Jan 25, 2024 16:18 UTC | P3 Health Partners Inc. PIII · Entity 4562 | GrantClass A Common Stock | 216,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-002240 · wk-form4_1706217492.xml · nonDerivative · entry 1 Price Thomas Edmunds · CIK 0001804153 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,561 F1 · shares: Represents a grant of restricted stock units ("RSUs") granted pursuant to the P3 Health Partners Inc. 2021 Incentive Award Plan. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest in two substantially equal installments on each of October 23, 2024 and October 23, 2025. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 17:13 UTC | P3 Health Partners Inc. PIII · Entity 4562 | GrantStock Option (Right to Buy) · Derivative | 85,535 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001104659-22-038855 · tm2210604-4_4seq1.xml · derivative · entry 1 Price Thomas Edmunds · CIK 0001804153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,535 Underlying: Class A Common Stock · 85,535 shares Expires 2032-03-24 F1 · derivative.exercise_date: The option vests and becomes exercisable with respect to 50% of the shares on each of March 24, 2023 and March 24, 2024. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:21 UTC | P3 Health Partners Inc. PIII · Entity 4562 | GrantCommon Units · Derivative | 1,177,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-147364 · tm2134662d13_4seq1.xml · derivative · entry 2 Price Thomas Edmunds · CIK 0001804153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,177,659 Underlying: Class A Common Stock · 1,177,659 shares Expires not disclosed F3 · security: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value. F4 · derivative.exercise_price: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for- one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration. F2 · shares: Includes 102,785 shares of Class V common stock and 102,786 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below). Also includes 134,359 shares of restricted Class V common stock and 134,359 restricted Common Units that vest on January 1, 2022. F3 · price: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value. F4 · derivative.exercise_date: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for- one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration. F4 · derivative.expiration_date: The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for- one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock for each Common Unit redeemed. Upon the redemption of any Common Units, a number of shares of Class V Common Stock of the Issuer equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration. F2 · balance_after: Includes 102,785 shares of Class V common stock and 102,786 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below). Also includes 134,359 shares of restricted Class V common stock and 134,359 restricted Common Units that vest on January 1, 2022. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:21 UTC | P3 Health Partners Inc. PIII · Entity 4562 | GrantClass V Common Stock | 1,177,659 | $117.77 | $138,692,900.43 |
DisclosureSEC source: 0001104659-21-147364 · tm2134662d13_4seq1.xml · nonDerivative · entry 1 Price Thomas Edmunds · CIK 0001804153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,177,659 F1 · security: Upon the redemption of any Common Units (as defined below), a number of shares of Class V Common Stock equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration. F2 · shares: Includes 102,785 shares of Class V common stock and 102,786 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below). Also includes 134,359 shares of restricted Class V common stock and 134,359 restricted Common Units that vest on January 1, 2022. F3 · price: At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the reporting person received Common Units of P3 Health Group, LLC (the "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchase price equal to par value. F2 · balance_after: Includes 102,785 shares of Class V common stock and 102,786 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance with the Merger Agreement (as defined below). Also includes 134,359 shares of restricted Class V common stock and 134,359 restricted Common Units that vest on January 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.